- United States
- /
- Semiconductors
- /
- NasdaqGS:AMBA
Is Ambarella’s (AMBA) Rising RS Rating Reframing Its Edge AI Chip Story With Investors?
Reviewed by Sasha Jovanovic
- Earlier this week, coverage highlighted how Ambarella’s push into AI-powered system-on-a-chip solutions for cameras and surveillance has helped lift its Relative Strength Rating from 74 to 81, signaling stronger technical momentum versus the broader market.
- This upgrade underscores how the company’s focus on AI-enabled edge processing is reshaping perceptions of its long-term role in advanced imaging and compute at the device level.
- Now, we’ll explore how this progress in AI-centric chip technology may influence Ambarella’s existing investment narrative around edge AI growth.
These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
Ambarella Investment Narrative Recap
To own Ambarella, you have to believe that AI-focused, edge-processing chips for cameras, IoT devices and automotive systems can grow into a much larger, more profitable business over time. The recent improvement in Relative Strength Rating suggests stronger technical momentum, but it does not materially change the near term catalyst, which is execution on AI SoC design wins, or the biggest current risk, which remains Ambarella’s reliance on volatile IoT and consumer video demand.
Recent quarterly results give useful context for that RS Rating move. In Q3 FY2026, Ambarella reported US$108.45 million in sales, up from US$82.65 million a year earlier, while narrowing its net loss to US$15.11 million from US$24.07 million. That mix of stronger top line and still negative earnings highlights both the appeal of its edge AI ramp and the risk that rising R&D and operating costs may outpace revenue if growth slows.
Yet investors should also be aware that growing AI revenues do not eliminate the risk that IoT cyclicality and customer concentration could still...
Read the full narrative on Ambarella (it's free!)
Ambarella's narrative projects $526.3 million revenue and $74.3 million earnings by 2028. This requires 14.8% yearly revenue growth and a $162.9 million earnings increase from -$88.6 million today.
Uncover how Ambarella's forecasts yield a $98.09 fair value, a 24% upside to its current price.
Exploring Other Perspectives
Seven fair value estimates from the Simply Wall St Community span roughly US$31 to US$105 per share, reflecting very different expectations. As you weigh those views, remember that Ambarella’s dependence on IoT and consumer video markets ties its performance to cycles in demand, inventory corrections and key customer decisions, which can all influence how those valuations play out over time.
Explore 7 other fair value estimates on Ambarella - why the stock might be worth as much as 33% more than the current price!
Build Your Own Ambarella Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Ambarella research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Ambarella research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ambarella's overall financial health at a glance.
Ready For A Different Approach?
Our top stock finds are flying under the radar-for now. Get in early:
- Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
- AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Mobile Infrastructure for Defense and Disaster
The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.
Get the investor briefing before the next round of contracts
Sponsored On Behalf of CiTechNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:AMBA
Ambarella
Develops semiconductor solutions that enable artificial intelligence (AI) processing, advanced image signal processing, and high-definition (HD) and ultra-HD compression.
Flawless balance sheet with very low risk.
Similar Companies
Market Insights
Weekly Picks
THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

The Quiet Giant That Became AI’s Power Grid
Recently Updated Narratives
Deep Value Multi Bagger Opportunity

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
